Press Releases

PLYMOUTH MEETING, Pa., May 31, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

The Compensation Committee of INOVIO's Board of Directors has approved the award of... (continue reading...)

The agreement marks an exciting first foray into the Canadian market for LAZ and will bring LAZ's best-in-class services to Canadian customers and clients; people-first focus to new team members. 

HARTFORD, Conn., May 31, 2024 /PRNewswire/ -- LAZ Parking, the largest, fastest-growing privately owned parking operator in the United States, is pleased to announce that it has been awarded a contract to manage parking services at Edmonton International Airport (YEG),... (continue reading...)

LAS VEGAS--(BUSINESS WIRE)-- Ault Disruptive Technologies Corporation, a special purpose acquisition company (the “Company”), today announced that in view of the unusual activity in the Company’s stock, the NYSE American, LLC (the “NYSE”) has contacted the Company in accordance with the NYSE’s usual practice and recommended that the Company respond by news release to the unusual activity.

Ordinarily, it is the Company’s policy not to comment on... (continue reading...)

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Prospect Floating Rate and Alternative Income Fund, Inc. (“Prospect Floating Rate and Alternative Income Fund” or the “Fund”), announced today that the Fund’s Board of Directors has declared monthly cash common shareholder distributions for May 2024.

The annualized total cash distribution is $0.35625 per share (7.5% annualized percentage rate based on the net asset value as of March 31, 2024), for a distribution... (continue reading...)

SUGAR LAND, Texas--(BUSINESS WIRE)-- Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares topline results of a randomized, placebo-controlled Phase II study (NCT05126563) to evaluate Hope Biosciences’ adipose‑derived allogeneic mesenchymal stem cell therapy (HB-adMSCs) for patients with Post‑COVID‑19 syndrome.

The trial enrolled 79 participants, with 39 subjects in the treatment group and 40 in the placebo... (continue reading...)